This paper presents a state-of-the-art review of using mobilized-peripheral blood progenitor cells (PBPC) for transplantation in children. Our own data and those from Medline searches and meeting reports, are analyzed and presented for the different sections that involve transplantation. Recommendations concerning the choice of mobilization regimens, venous access, priming of separator extracorporeal line, anticoagulation, and number of CD34 + cells to infuse for rapid engraftment are proposed. In the allogeneic setting, we analyze ethical and safety aspects of pediatric donor mobilization and collection. Data from the literature suggest that the use of cytokine-mobilized PBPC for allogeneic transplantation appears to be safe both for pediatric donors and patients leading a rapid hematopoietic engraftment with a similar incidence of acute graftversus-host disease (GVHD). The high incidence of chronic GVHD and its management emerge as the most concerning aspect in allogeneic PBPC transplantation. Bone Marrow Transplantation (2000) 26, 1291-1298.
Over the past decade, several reports [1] [2] [3] showed that mobilized PBPC could be used for autologous transplantation in pediatric patients. Since then, autologous PBPC have increasingly been used as source of hematopoietic stem cells in different treatment protocols having almost replaced autologous bone marrow transplantation. Among the reasons for this are the ease of collecting high numbers of stem cells from peripheral blood and the lower use of economical resources as compared to bone marrow. More recently this technology has rapidly emerged in allogeneic transplantation in adults [4] [5] [6] and in pediatric patients [7] [8] [9] [10] with encouraging results.
However, in children as compared to adults there is still an imbalance between bone marrow vs PBSC grafts. Moreover, as far as the smallest children are concerned, there are only limited published data about harvest, ex vivo treatment and the clinical use of PBSCs. [11] [12] [13] [14] [15] [16] [17] [18] In this article we review some technical, clinical and biological aspects of using PBPC in children in autologous and allogeneic situations. This review is based on our own experience of the Madrid (Spain) and Clermont-Ferrand (France) teams and also on the most important published experiences.
PBPC mobilization
The ideal mobilization technique should be one that allows the collection of a large number of hematopoietic cells, but does not alter the patient's treatment. In the autologous setting, PBPC collection after chemotherapy with or without cytokines may (1) reduce tumor contamination in the graft; (2) increase the PBPC number; and (3) avoid the delay in underlying disease treatment while PBPC are being collected. However, the optimal method for PBPC mobilization in children is still unknown.
Chemotherapy mobilization with or without cytokines
In adults, several reports 19, 20 have demonstrated that chemotherapy followed by administration of hematopoietic growth factors results in the greatest PBPC mobilization. In children either disease-based chemotherapy or more specific 'mobilizing' chemotherapy regimens have been used to mobilize. 11 Although no prospective and randomized studies have investigated the role of adding hematopoietic growth factors, mainly G-CSF and GM-CSF, to chemotherapy regimens several clinical trials have shown that addition of G-or GM-CSF (5-10 g/kg/day) to a variety of chemotherapy-mobilizing regimens led to an eight-fold greater yield of PBPC compared to chemotherapy mobilization alone. 21 
Mobilization with cytokines alone
Mobilization regimens based on either chemotherapy or chemotherapy + hematopoietic growth factors have limitations such as hematopoietic toxicity, hospitalization and most importantly unpredictability of timing collections. On the other hand, the timing of harvest can be adequately planned when G-CSF alone is used as mobilization agent. Kanold et al 21 conducted a clinical trial comparing effectiveness of mobilization between G-CSF alone and G-CSF or GM-CSF added to chemotherapy regimens, and there were no consistent differences in the number of PBPC collected. A study regarding kinetics of hematopoietic cell release induced by G-CSF alone was performed in children and provide data which can be used to plan leukapheresis procedures.
14 Other studies 22 have demonstrated that PBPC collected following mobilization with G-CSF alone are effective in reconstituting hematopoiesis after myeloablative therapy in pediatric patients with cancer.
An open issue is the optimal dose of G-CSF for mobilization. Although no randomized studies in adults are available, current data suggest a dose-response effect when G-CSF is used for PBPC mobilization. 23, 24 In a recent study in children, the degree of CD34 + mobilization was found to be higher in patients receiving G-CSF at a dose of 20 g/kg/day than in patients who received 10 g/kg/day. However, no significant differences were found in terms of collected CD34
+ cells in both groups. 25 Recently recommendations have been made by a European panel regarding the use of colony-stimulating factors in children. They suggest that for children needing autologous PBPC transplantation G-CSF can be administered alone at a dose of 10 g/kg/day for 4-5 days beginning collections after the fourth dose. 26 
Mobilization in pediatric donors
G-CSF has been most extensively used for donor mobilization 27 due to its proven efficacy in cancer patients and its lesser side-effects compared with other cytokines. 28 The most widely used protocol consists of administration of a 4-day course at a dose of 10 g/kg/day performing collections on days 5 and 6. In pediatric donors, few data are available regarding the safety of PBPC mobilization and collection. [7] [8] [9] [10] [29] [30] [31] Potential risk factors are not only associated with the mobilization regimen but are also collection-related such as line placement, bleeding or citrate toxicity. These potential risk factors are more important when donors are very small. Thus, there is a general reluctance to consider PBPC mobilization when the donor is a minor. The ethical considerations should also be debated whenever a small child is considered for a bone marrow donation. 32 Data from the literature suggest that they tolerate mobilization at the same G-CSF doses better than adults. 8, 30, 31, [33] [34] [35] [36] [37] In fact, commonly reported short-term side-effects related to G-CSF (bone pain, slight fever, fatigue and elevation of serum alkaline phosphatase and transaminases) were observed essentially in donors aged more than 20 years and no complaints were made by pediatric donors who maintained their normal activity. However, data about the longterm safety of G-CSF are currently rare 38 and some cases of severe complication have been described in adult donors. [39] [40] [41] Recently, Kawano et al 30 have compared the mobilization kinetics in pediatric and adult donors. While the serum level of G-CSF was significantly lower in pediatric than in adult donors there were no differences either in mononuclear cell values or in the percentage of CD34 + cells. They also suggested that a higher dose of G-CSF may be indicated in pediatric donors. On the other hand, it was suggested by Watanabe et al 42 that a lower G-CSF dose might be able to induce a sufficient increase in circulating progenitor cells in children.
PBPC collection
Experience with PBPC collection in children, specially in very small ones, is still limited because of potential problems which are specific to children: vascular access difficulties and low total blood volume (TBV).
Venous access and related complications
Most teams use a special temporary catheter for leukapheresis which may be single or double lumen. [43] [44] [45] [46] [47] [48] Few teams use peripheral venous access together with a central catheter installed at diagnosis. 12, 49 Only when it is deemed impossible to ensure adequate blood flow with peripheral veins is a CVC installed under local anesthesia and sedation. 50 Peripheral venous access provides several advantages. It avoids the need for an invasive procedure with general anesthesia and reduces the risk of infections. It is an unresolved issue what CVC should be used for this purpose. In general, they should have classical dialysis or apheresis characteristics such as multiple holes, port offset and made with rigid materials. Non-tunneled CVCs are preferable due to the fact that they may be placed under local anesthesia or sedation at the bedside into femoral or subclavian veins, and may be removed without surgery after PBPC collection. 50 Mechanical CVC complications are not uncommon. There are reported cases of pneumothorax, occlusion and thrombosis, placement and dislodgment problems. 11, 16, 22, 30, 46 Many of the serious complications (pneumo-or hematothorax, pleural infusion) can be avoided by using femoral access. On the other hand, concerns for an increased incidence of infections arise with use of this site. However, the pericollection infectious episodes are very difficult to evaluate because the majority of authors report on this complication in long-term use (both pericollection and transplant periods). Leibundgut et al 51 in a prospective study reported 0.26 septic events per 100 catheter days with tunneled double lumen Broviac catheters installed for PBPC harvest and transplant.
Priming of the extracorporeal volume
At leukapheresis, particular attention must be paid to hemodynamic changes due to acute blood volume subtraction. The most frequent reported hemodynamic problems are transient and reversible hypotensive episodes 46 and hypothermia. 47 Although there is no agreement regarding the way to prevent this complication a practical approach to this issue is priming extracorporeal line. Priming is usually performed with concentrated red blood cells (RBC) but combinations of RBC, human serum albumin (HSA) and NaCl are also used by some teams. 18 44, 57 depending on the team. Today priming is usually reserved for patients with a TBV of less than one liter or for patients for whom the extracorporeal volume represents more than 25% of their TBV. At the end of apheresis, reinfusion procedures should be deleted in very small patients that require RBC priming to avoid volume overload.
Anticoagulation
Apheresis procedures require anticoagulation to prevent clotting of the extracorporeal line. Acid-citrate dextrose (ACD-A) anticoagulation used traditionally by the majority of authors is usually well tolerated.
11,18,21,22,52,58 Some authors have successfully used an anticoagulation regimen with low-dose ACD-A and heparin boluses. 16 An alternative regimen 59 involves a solution of 500 ml ACD-A plus 5000 IU of preservative-free heparin infused at a whole blood to an anticoagulation ratio of 30:1. The most important reported side-effect is hypocalcemia. 12 This may represent a serious problem specially in very young children because of their particular risk of hypocalcemia. Hypocalcemia can be prevented using continuous or bolus infusion of calcium gluconate into the return line during the leukapheresis procedure 12 or oral calcium gluconate (dose of 0.5 g/10 kg) before and during collection. 58 It also can be prevented by reducing the AC infusion rate to less than 1.0 ml/min/l.
Other toxicities
Hematologic toxicity is constant. Cases of profound cytopenias have been reported.
11,22,46

Large-volume leukapheresis (LVL)
Technical problems along with the psychological impact of leukapheresis in children made reducing the number of leukapheresis procedures desirable. This may be accomplished by LVL. LVL is defined as processing the patient's TBV at least three times in a single procedure. It has been safely and easily performed in adults and in older children. Four teams have recently published papers on the LVL technique in the smallest of children (up to 25 kg) and about 150 procedures have been reported. 13, 16, 17, 49, 60 The number of TBV processed during one leukapheresis ranged from 3 to 11, 16 with a median procedure duration of 4 h. The majority of these leukaphereses were performed with priming the extracorporeal volume with RBC and one double or two single central lines. In terms of collection efficiency 4.5 to 8 × 10 6 CD34 + cells/kg were harvested during one leukapheresis. At Niño Jesus Children's Hospital, we have observed that LVL is well tolerated by children. The procedures were performed without sedation, with little difficulty, and allowed us to collect PBPC efficiently and safely. The procedure time was long (median Bone Marrow Transplantation 321 min, range 204-511 min) due to the high TBV processed (median 4.9, range 3.3-7.7), but in a familiar and relaxed environment with parents present and psychological preparation, discomfort was not seen in the children. In Clermont Ferrand, in children weighing 15 kg or less, no clinical complications of LVL were observed. However, we noted (1) an increase in the rate of special catheter installation as compared to our standard procedure; (2) an important decrease of hemoglobin level in children who had not had extracorporeal line priming or excessive priming/transfusion; and (3) profound platelet loss. In our opinion, this approach is preferable to more than one session and it offers economic and logistic advantages but in the smallest patients it should be considered only when a very large number of cells must be collected and should be performed only by an experienced team.
Collection in the smallest of children
There are few reports focused on PBPC collection in very small children. [11] [12] [13] [14] [15] [16] 18, 51 In a study conducted by Kanold et al, 15 109 leukapheresis procedures performed in children weighing less than 15 kg were analyzed. The median number of CD34 + cell derived from one patient's blood volume was 1.1 × 10 6 /kg (5.9 × 10 6 /kg in 1-4 leukaphereses). No signs of citrate toxicity or hypotensive episodes were noticed. The only toxicity observed was a significant decrease in platelet count following each procedure (median 38% decrease). In a study carried out by Diaz et al, 13 a smaller apheresis number (mean 1.1, median 1, range 1-3) was needed to harvest the targeted PBPC number and the minimum requirement of 1 × 10 6 /kg CD34 + cells was collected in a single apheresis in 84% of patients. Takaue et al 11 evaluated the safety and efficacy of harvesting PBPC by leukaphereses in 38 children weighing 20 kg or less. A total of 81 procedures was performed (mean 2.1; range, 1-4) mainly following chemotherapy mobilization using a CS-3000 Fenwall cell separator (Fenwall, Deerfield, IL, USA). The average rate of inlet flow was 30 ml/min (range, . The blood volume per kg processed per apheresis ranged from 85 to 615 ml (median, 270 ml) and all apheresis procedures were finished within 3 h. The median number of PBPC yielded per apheresis was 34 × 10 4 /kg for CFU-GM and 15 × 10 6 /kg for CD34 + cells. In all patients severe thrombocytopenia was observed and they required reinfusion of the platelet-rich plasma collected during apheresis.
It has also been found that increases in patient body weights and ages, and the amount of previous chemotherapy, all have a negative effect on CD34
+ -cell mobilization. 13 However, in patients weighing Ͻ25 kg, the negative effect of the amount of previous chemotherapy was not observed. 13 This finding may be due to differences in the proliferative capacity of hematopoiesis between smaller and older children and therefore more PBPC could be collected from smaller children as suggested by Takaue et al. 11 Nevertheless, patients with neuroblastoma had a significantly lower yield than other patients. 13 Optimization of peripheral blood progenitor cell PBPC collections remains to be resolved especially in pediatric patients undergoing PBPC mobilization by G-CSF alone, mainly due to the high inter-patient PBPC mobilization variability. Most studies suggest that PBPC yield may be predicted from pre-apheresis peripheral blood CD34 + cell counts.
14,15
PBPC selection
PB CD34
+ cells are increasingly used as the sole source of hematopoietic progenitor cells for grafting following highdose therapy for malignant diseases as the ability of these cells to reconstitute hematopoiesis has been demonstrated. 61, 62 However, the published clinical trials of CD34 + cell transplantation have mainly been performed in adults [63] [64] [65] [66] and there are only a few reports of significant studies performed in children. 43, [67] [68] [69] The majority of these pediatric patients are children with advanced neuroblastoma. One of the potential benefits of CD34 + enrichment of PBPC or bone marrow autografts is the concomitant depletion of tumor cell levels. 66, 70 Although the clinical significance of malignant clonogenic cell contamination of the grafts is still unclear, gene marking studies in patients with neuroblastoma performed by Brenner et al 71 have demonstrated that contaminating tumor cells within the transplant may contribute to relapse. 72 In Clermont-Ferrand, since we have observed that neuroblastoma cells contaminate 83% of our leukapheresis products as assessed by RT-PCR for thyrosine hydroxylase assay, 73, 74 we decided to perform PB CD34 + cell selection. So far this has been carried out in 34 children. First we demonstrated the feasibility of positive PB CD34
+ cell selection. The products of two leukaphereses (which represent a total of approximately five patient blood volumes processed) are pooled for selection being the lower limit for acceptable collection of 3 × 10 6 CD34 + cells/kg. 75, 76 The purge effect is in the order of 2-3 log. In the context of a multicentric prospective study, 23 patients with advanced neuroblastoma were grafted with CD34 + cells after busulfan/melphalan conditioning. The goals of this study were to evaluate hematopoietic and immune recovery and long-term follow-up. 77 Concerning hematopoietic recovery the results were: neutrophil recovery a median of 12 days, platelet recovery a median of 60 days. Overall survival is greater than 50% after 4 years followup. However, we have noted first a persistent decrease in CD4
+ lymphocyte levels and a high incidence of serious and life-threatening late complications (two patients had EBV-associated lymphoproliferation, six children had severe VZV infection and six severe septic shock events occurred after completion of hematopoietic reconstitution); second, a delayed platelet recovery which is longer than in historical series. 78, 79 Other published experience of PB CD34
+ cell selection in children 43, 69 confirms the feasibility of this technique and a successful short-term engraftment of PB CD34 + cells. However, in children as well as in adults' questions concerning the use of ex vivo modified PBPCs remain open: to define categories of patients for whom selection is beneficial and to balance the advantages and disadvantages of grafting selected cells.
Engraftment kinetics
Analysis of engraftment kinetics in pediatric patients is very important to optimize apheresis procedures and save costs. In adult patients the PBPC target for transplantation varies between 2.5 and 5.0 × 10 6 /kg CD34 + cells and a threshold effect has been observed. [80] [81] [82] Patients who received more than 5.0 × l0 6 /kg CD34 + cells had a more rapid neutrophil and platelet engraftment than patients grafted with a smaller number of CD34 + cells. In a cohort of 46 pediatric patients who underwent autologous PBPC transplantation, serial threshold values were found for neutrophil recovery. 44 Ninety-five percent of patients who received more than 5.0 × 10 6 /kg CD34 + cells achieved a neutrophil recovery on day 9 whereas patients who received fewer than 1.0 × 10 6 /kg CD34 + cells achieved neutrophil recovery on day 15. It was impossible to define a minimum number of CD34 + cells to infuse because seven patients who received less than 1.0 × 10 6 /kg CD34 + cells achieved neutrophil recovery. Analysis of certain CD34
+ cell subsets could be particularly useful in predicting the repopulating capacity of leukapheresis products when a low number of CD34 + cells is infused. [83] [84] [85] The speed of platelet recovery also correlated with the number of CD34 + infused cells. Ninety-five percent of patients who received more than 5.0 × 10 6 /kg CD34 + cells achieved platelet recovery on day 33 (20 × 10 9 /l) and day 35 (50 × 10 9 /l) whereas patients who received less than 1.0 × 10 6 /kg CD34 + cells platelet recovery occurred on days 35 and 93, respectively. We believe that platelet engraftment kinetics was rather long probably due to the negative impact of post-infusion G-CSF on platelet recovery as previously reported by others. 81 More recently, Diaz et al 86 + cell group resulted in less transfusional support, fewer days on i.v. antibiotics and shorter hospitalization. This study confirms that G-CSF-mobilized PBPC provide rapid short-and long-term hematopoietic engraftment in pediatric patients undergoing autologous transplantation if a CD34
+ cell dose у5.0 × 10 6 /kg is infused. As this PBPC dose seems to have clinical and potentially economic implications, it should be considered the optimal target for apheresis. A minimum of 1.0 × 10 6 /kg CD34 + cells might be sufficient to ensure neutrophil engraftment but insufficient for platelet recovery. Thus for us the minimum CD34 + cell dose has been augmented (у2 × 10 6 /kg).
86
Allogeneic transplantation with PBPC
In 1989, the first allogeneic PBPC transplantation (allo-PBPCT) in adults was performed by Kessinger et al. 87 Four years later, Russell et al 88 published the successful use of PBPC G-CSF-mobilized for allogeneic transplantation. Other reports [4] [5] [6] of allo-PBPCT in adults clearly show that this therapeutic procedure provides advantages over bone marrow for donors and recipients. For donors, avoidance of general anesthesia, marrow harvesting, blood transfusions and hospitalization are undoubted advantages. 89, 90 The benefits for recipients are faster hematopoietic engraftment and immune reconstitution compared to allogeneic bone marrow transplantation (allo-BMT). [4] [5] [6] [91] [92] [93] [94] Although a PBPC graft contains 10 to 20-fold more T cells than does a bone marrow graft, a similar incidence of acute GVHD has been observed. However, chronic GVHD might be more frequent. 95 In those studies, allo-PBPCT was used mainly in adult patients with advanced hematological malignancies. However, there is very limited reported experience using allo-PBPCT in pediatric patients. [7] [8] [9] 75, 96 As pointed out by Miniero et al, 76, 97 this fact reflects the reluctance of many transplant centers to consider PBPC mobilization when the donor is a minor. First reports on allo-PBPCT in children were published in 1996 by Villa et al 9 and Körbling et al. 7 Both studies involved a small number of patients and explored procedure feasibility. All recipients achieved hematopoietic engraftment and mobilization-related severe short-term side-effects in pediatric donors were not reported. Results from one study 10 suggest that allo-PBPCT may have advantages for engraftment kinetics over allo-BMT without an increased incidence of severe GVHD. Data from the literature [7] [8] [9] 75, 76, 97, 98 suggest that allo-PBPCT appears to be safe for pediatric donors, yields enough progenitor cells and results in prompt engraftment. The median time for engraftment (neutrophil count у0.5 × 10 9 /l and platelet count Ͼ20 × 10 9 /l) ranged from 10 to 16 days and from 12 to 18 days, respectively. 10, 75, 76, 97, 98 Rapid engraftment was observed when methotrexate was not part of the GVHD prophylaxis regimen. 98 The reported incidence of acute GVHD ranged from 20% to nearly 50%, being mainly influenced by using methotrexate along with cyclosporine as the GVHD prophylaxis regimen. 98 Levine and colleagues 98 in a recent study involving 24 pediatric patients, found an incidence of chronic GVHD of 75% at 1 year. This finding is comparable to those reported by others for adult patients. 99, 100 It has been suggested that a reduced risk of leukemia relapse is associated with chronic GVHD. 101 However, as pointed out by others, 96 it is unclear whether the possible advantages of a superior graft-versusleukemia effect outweigh the disadvantage of more frequent chronic GVHD.
Conclusions
PBPC mobilization regimens in children must provide a programmable timing of collections reducing its numbers and thus the psychological impact, be simple enough to be carried out as out-patients and not add toxicity either to treatment or to graft procedure. In our experience, mobilizBone Marrow Transplantation ation by G-CSF alone in steady state hematopoiesis meets these conditions. Collection of PBPC in the smallest of children is feasible and controllable in a satisfactory manner. However, certain pre-conditions must be met in order to perform effective and safe PBPC harvest: a specific pediatric collection team working in a dedicated pediatric environment and a close collaboration between the collection and transplantation teams. We consider that now is the time to define accepted standards for pediatric leukapheresis and to provide written Good Medical Practice specifically for this technique. In the allogeneic setting, it is still too early to conclude with recommendations, but this therapeutic procedure should not be used outside a clinical trial which should be approved by the Institutional Review Boards because the long-term safety of cytokine mobilization in healthy pediatric donors is still an open question.
